Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06194-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Simon Østergaard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark. simoo@regionsjaelland.dk. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Cell Transformation, Neoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Copenhagen University.
Abstract (Originalsprache)
Central nervous system (CNS) involvement in Waldenström macroglobulinemia (WM) is a rare complication that can manifest as Bing-Neel syndrome (BNS) or as histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL). We report data from a single-center cohort of 469 patients consecutively diagnosed with WM between 2000 and 2022. BNS was identified in 1.5% ( n = 7) and HT with CNS involvement (CNS-HT) in 1.7% ( n = 8) of patients. The cumulative incidence of BNS and CNS-HT at 15 years was 2.6% and 2.7%, respectively, with CNS-HT more likely to develop in closer proximity to the initial WM diagnosis. One patient with CNS-HT exhibited a preceding phase of BNS before transformation. In general, patients with BNS and CNS-HT presented with diverse neurological symptoms and clinical features. Parenchymal lesions were uniformly found in all patients with CNS-HT, while neuroimaging findings were less consistent in patients with BNS. Involvement of multiple extramedullary sites was observed in approximately half of the patients with both BNS and CNS-HT. Patients with CNS-HT had poor outcomes, with a median overall survival of 10 months following the onset of CNS involvement, whereas BNS was associated with a more favorable prognosis, particularly in patients treated with ibrutinib. This study is the first to present a comparative analysis of BNS and CNS-HT in WM, providing novel insights into their incidence, clinical features, and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark. simoo@regionsjaelland.dk.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. simoo@regionsjaelland.dk.
- Department of Hematology, Zealand University Hospital Roskilde, Roskilde, Denmark.
- Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Danish Medicines Agency, Copenhagen, Denmark.
- Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.
Förderung
- Copenhagen University
Zitieren
APA
Østergaard, S., Munksgaard, L., Hammer, T., Nielsen, T. H., Pedersen, M. Ø., & Gjerdrum, L. M. R. (2025). Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation. Annals of Hematology. https://doi.org/10.1007/s00277-025-06194-4
Vancouver
Østergaard S, Munksgaard L, Hammer T, Nielsen TH, Pedersen MØ, Gjerdrum LMR. Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation. Annals of Hematology. 2025. doi:10.1007/s00277-025-06194-4
BibTeX
@article{stergaard2025,
author = {Østergaard, Simon and Munksgaard, Lars and Hammer, Troels and Nielsen, Torsten Holm and Pedersen, Mette Ølgod and Gjerdrum, Lise Mette Rahbek},
title = {Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06194-4}
}
EUVIMED